Track topics on Twitter Track topics that are important to you
TEL AVIV, Israel, March 01, 2017 (GLOBE NEWSWIRE) -- Alcobra Ltd. (NasdaqGM:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat central nervous system and cognitive disorders, today announced that it will host an investor forum on Tuesday, March 28, 2017 from 8:00-9:30 a.m. EST in New York City. The forum will feature several experts in the field of prescription medication abuse and the treatment and management of attention deficit and hyperactivity disorder (ADHD). In addition, Alcobra’s executive management team will provide an evidence-based overview of the commercial potential for its proprietary Abuse-Deterrent, Amphetamine Immediate Release product candidate called ADAIR.
At the forum, Dr. Timothy Wilens and Dr. Stephen Faraone will provide a general overview and answer questions regarding prescription medication abuse and the treatment and management of ADHD. Timothy Wilens, M.D. is chief, Division of Child and Adolescent Psychiatry and co-director Center for Addiction Medicine at Massachusetts General Hospital (MGH). He is also associate professor of psychiatry at Harvard Medical School in Boston. His residency in child, adolescent, adult, and addiction psychiatry was completed at MGH under the auspices of Harvard Medical School. Dr. Wilens' research interests include the relationship among attention deficit and hyperactivity disorder (ADHD), bipolar disorder and substance use disorders, and the pharmacotherapy of ADHD across the lifespan.
Stephen Faraone, Ph.D., vice president of the World Federation of ADHD, studies the nature and causes of mental disorders in childhood. In 2014, 2015 and 2016 Thompson Reuters named Dr. Faraone one of the world’s most highly cited scholars in the fields of psychiatry and psychology. He is an author on over 800 journal articles, editorials, chapters and books, his research interests include genetics, biomarker development, psychopharmacology and research methodology. Dr. Faraone is editor for the journal Neuropsychiatric Genetics and also deputy editor for the Journal of the American Academy of Child and Adolescent Psychiatry.
The event will be webcast live beginning at 8:00 a.m. EST. The webcast and accompanying presentation materials will be accessible live and archived on the Investor Relations section of Alcobra’s website at www.alcobra-pharma.com, the content of which is not incorporated herein by reference.
To attend the event in person, please contact the company at email@example.com.
Alcobra's Abuse-Deterrent Amphetamine Immediate-Release (ADAIR) product candidate is a proprietary, abuse-deterrent oral formulation of immediate-release (short-acting) dextroamphetamine that is currently under development for the treatment of ADHD. ADAIR is being specifically designed to limit abuse by snorting or injecting. The U.S. Department of Health and Human Services reported recently that approximately five million people misuse or abuse prescription stimulants annually in the US, with studies reporting that 40 percent or more do so by snorting or injecting these products. The ADAIR formulation was developed in close collaboration with Capsugel, a global leader in delivering high-quality, innovative dosage forms and solutions.
Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of medications to treat CNS and cognitive disorders. For more information, please visit the company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.
Investor Contacts Alcobra Investor Relations Debbie Kaye US: 212-390-8964, Intl: +972-3-7299871 IR@alcobra-pharma.comNEXT ARTICLE
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...
A prescription drug (also prescription medication or prescription medicine) is a licensed medicine that is regulated by legislation to require a medical prescription before it can be obtained. The term is used to distinguish it from over-the-counter drug...